-
functional neuroimaging data. Specific activities may include managing/preprocessing/analyzing behavioral and neuroimaging data, collecting new data (e.g., behavioral task, fMRI, digital phenotyping via mobile
-
serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and
-
therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust
-
fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of
-
, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of
-
fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of
-
managing/preprocessing/analyzing behavioral and neuroimaging data, collecting new data (e.g., behavioral task, fMRI, digital phenotyping via mobile phone, wearables), presenting and disseminating research